We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
Read MoreHide Full Article
Novavax (NVAX - Free Report) closed the most recent trading day at $10.11, moving +1.1% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.17%. Meanwhile, the Dow lost 0.18%, and the Nasdaq, a tech-heavy index, added 0.4%.
Prior to today's trading, shares of the vaccine maker had gained 18.76% outpaced the Medical sector's gain of 0.65% and the S&P 500's loss of 1.29%.
The upcoming earnings release of Novavax will be of great interest to investors. The company's earnings per share (EPS) are projected to be -$0.37, reflecting a 40.32% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $42.96 million, down 39.01% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.46 per share and revenue of $357.88 million. These totals would mark changes of -117.83% and -68.15%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for Novavax. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been a 7.86% fall in the Zacks Consensus EPS estimate. Novavax presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 161, which puts it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow NVAX in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
Novavax (NVAX - Free Report) closed the most recent trading day at $10.11, moving +1.1% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.17%. Meanwhile, the Dow lost 0.18%, and the Nasdaq, a tech-heavy index, added 0.4%.
Prior to today's trading, shares of the vaccine maker had gained 18.76% outpaced the Medical sector's gain of 0.65% and the S&P 500's loss of 1.29%.
The upcoming earnings release of Novavax will be of great interest to investors. The company's earnings per share (EPS) are projected to be -$0.37, reflecting a 40.32% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $42.96 million, down 39.01% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.46 per share and revenue of $357.88 million. These totals would mark changes of -117.83% and -68.15%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for Novavax. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been a 7.86% fall in the Zacks Consensus EPS estimate. Novavax presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 161, which puts it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow NVAX in the coming trading sessions, be sure to utilize Zacks.com.